Search

Buprenorphine

[L46571] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid … Clinically, this results in a slow onset of action and a clinical phenomenon known as the "ceiling effect" where once a certain dose is reached, buprenorphine's effects plateau.

Cod liver oil

Also being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. … Cod liver oil is extracted from the liver of cod fish and mainly consists of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Clofarabine

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed.

Isotretinoin

[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. … Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.

Aflibercept

[A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment

Venlafaxine

Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). … It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).

Rifaximin

It is marketed under the brand name Xifaxan by Salix Pharmaceuticals. … indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D)

Elosulfase alfa

Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. … Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome.

Phosphorus

Agalsidase alfa

[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta].